{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:29:38Z","timestamp":1786415378432,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05740-9","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:55:05Z","timestamp":1786413305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benchmarking of Saudi pharmacovigilance inspection standards across international regulatory authorities"],"prefix":"10.1007","author":[{"given":"Mashael","family":"Alhadaithy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alsaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Aldali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"5740_CR1","unstructured":"21 CFR 312.53 (n.d.) Selecting investigators and monitors. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-312\/subpart-D\/section-312.53. Accessed 19 Aug 2025"},{"key":"5740_CR2","unstructured":"Arafah A, AlOtaibi AA, Al Dali HA (2023) Pharmacovigilance compliance among Marketing Authorisation holders in Saudi Arabia [Internet].\u00a0Available from: https:\/\/uppsalareports.org\/articles\/pharmacovigilance-compliance-among-mahs-in-saudi-arabia\/. Accessed 20 Sept 2025"},{"issue":"10","key":"5740_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/heapol\/czaa064","volume":"35","author":"SL Dalglish","year":"2021","unstructured":"Dalglish SL, Khalid H, McMahon SA (2020) Document analysis in health policy research: the READ approach. Health Policy Plan 35(10):1424\u20131431. https:\/\/doi.org\/10.1093\/heapol\/czaa064","journal-title":"Health Policy Plan"},{"key":"5740_CR4","unstructured":"European Medicines Agency (2012) Guideline on good pharmacovigilance practices (GVP): module I \u2013 pharmacovigilance systems and their quality systems [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-and-their-quality-systems_en.pdf. Accessed 7 Aug 2025"},{"key":"5740_CR5","unstructured":"European Medicines Agency (2013) Pharmacovigilance inspection policy for centralised procedures: medicinal products for human use [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/pharmacovigilance-inspection-policy-centralised-procedures-medicinal-products-human-use_en.pdf. Accessed 13 Aug 2025"},{"key":"5740_CR6","unstructured":"European Medicines Agency (2014) Guideline on good pharmacovigilance practices (GVP): Module III \u2013 Pharmacovigilance inspections (Rev 1) [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections_en.pdf. Accessed 3 Aug 2025"},{"key":"5740_CR7","unstructured":"European Medicines Agency (2015) Guideline on good pharmacovigilance practices (GVP): module IV \u2013 pharmacovigilance audits (Rev. 1) [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-iv-pharmacovigilance-audits-rev-1_en.pdf. Accessed 7 Aug 2025"},{"key":"5740_CR8","unstructured":"European Medicines Agency (2017) Guideline on good pharmacovigilance practices (GVP): module II \u2013 pharmacovigilance system master file (Rev. 2) [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev-2_en.pdf. Accessed 4 Aug 2025"},{"key":"5740_CR9","unstructured":"European Medicines Agency (2020) Annual report of the pharmacovigilance inspectors working group for 2018 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/annual-report-pharmacovigilance-inspectors-working-group-2018_en.pdf. Accessed 11 Aug 2025"},{"key":"5740_CR10","unstructured":"European Medicines Agency (2021) Annual report of the Pharmacovigilance Inspectors Working Group 2019\u20132020 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/annual-report-pharmacovigilance-inspectors-working-group-2019-2020_en.pdf. Accessed 11 Aug 2025"},{"key":"5740_CR11","unstructured":"European Medicines Agency (2023a) Annual report of the pharmacovigilance inspectors working group 2021\u20132022 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/annual-report-pharmacovigilance-inspectors-working-group-2021-2022_en.pdf. Accessed 13 Aug 2025"},{"key":"5740_CR12","unstructured":"European Medicines Agency (2023b) Implementation of the pharmacovigilance legislation [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/pharmacovigilance-overview\/legal-framework-pharmacovigilance\/implementation-pharmacovigilance-legislation. Accessed 3 Aug 2025"},{"key":"5740_CR13","unstructured":"European Medicines Agency (2023c) United States [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/partners-networks\/international-activities\/bilateral-interactions-non-eu-regulators\/united-states#confidentiality-arrangements-10561. Accessed 15 Aug 2025"},{"key":"5740_CR14","unstructured":"European Medicines Agency (2024) Annual report of the pharmacovigilance inspectors working group for 2023 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/report\/annual-report-pharmacovigilance-inspectors-working-group-2023_en.pdf. Accessed 13 Aug 2025"},{"key":"5740_CR15","unstructured":"International Council for Harmonisation (n.d.) Efficacy guidelines [Internet].\u00a0Available from: https:\/\/www.ich.org\/page\/efficacy-guidelines.\u00a0Accessed 20 July 2025"},{"key":"5740_CR16","unstructured":"International Council for Harmonisation (n.d.) Members & Observers [Internet]. Available from: https:\/\/www.ich.org\/page\/members-observers. Accessed 22 July 2025"},{"key":"5740_CR17","unstructured":"Saudi Food and Drug Authority (2025) Guideline on Good Pharmacovigilance Practices (GVP), Version 4.0 [Internet]. Available from: https:\/\/sfda.gov.sa\/sites\/default\/files\/2025-08\/Drug-GVP4_0.pdf. Accessed 1 Sept 2025"},{"key":"5740_CR18","unstructured":"U.S. Food and Drug Administration (n.d.) FDA Inspections Data Dashboard [Internet]. Available from: https:\/\/datadashboard.fda.gov\/oii\/cd\/inspections.htm. Accessed 16 Aug 2025"},{"key":"5740_CR19","unstructured":"U.S. Food and Drug Administration (2006) A History of the FDA and Drug Regulation in the United States [Internet]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/A-History-of-the-FDA-and-Drug-Regulation-in-the-United-States.pdf. Accessed 18 Aug 2025"},{"key":"5740_CR20","unstructured":"U.S. Food and Drug Administration (2021) What to Expect After an Inspection [Internet]. Available from: https:\/\/www.fda.gov\/media\/156347\/download. Accessed 24 Aug 2025"},{"key":"5740_CR21","unstructured":"U.S. Food and Drug Administration (2022) Postmarketing adverse drug experience (PADE) inspections compliance program for human drug and therapeutic biological products. Compliance Program Guidance Manual 7353.001. Silver Spring (MD): FDA. Available from: https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/drug-compliance-programs"},{"key":"5740_CR22","unstructured":"U.S. Food and Drug Administration (2025a) Conducting remote regulatory assessments: questions and answers. Guidance for Industry [Internet]. Available from: https:\/\/www.fda.gov\/media\/160173\/download. Accessed 26 Aug 2025"},{"key":"5740_CR23","unstructured":"U.S. Food and Drug Administration (2025b) Investigations Operations Manual (IOM), Chapter 5 \u2013 Inspections. Available from: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/inspection-references\/investigations-operations-manual. Accessed 20 Aug 2025"},{"key":"5740_CR24","unstructured":"U.S. Food and Drug Administration (2025c) Mutual Recognition Agreements (MRA) [Internet]. Available from: https:\/\/www.fda.gov\/international-programs\/international-arrangements\/mutual-recognition-agreements-mra. Accessed 15 Aug 2025"},{"key":"5740_CR25","unstructured":"World Health Organization (n.d.) Pharmacovigilance [Internet].\u00a0Available from: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance.\u00a0Accessed 17 July 2025"},{"key":"5740_CR26","unstructured":"World Health Organization (2023) Saudi Arabia regulatory system becomes third to reach WHO Maturity Level 4 [Internet]. Available from: https:\/\/www.who.int\/news\/item\/30-10-2023-saudi-arabia-regulatory-system-becomes-third-to-reach-who-maturity-level-4. Accessed 23 July 2025"},{"key":"5740_CR27","unstructured":"World Health Organization (2024) Largest number of regulatory agencies for medical products approved as WHO Listed Authorities [Internet]. Available from: https:\/\/www.who.int\/news\/item\/20-05-2024-largest-number-of-regulatory-agencies-for-medical-products-approved-as-who-listed-authorities. Accessed 22 July 2025"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05740-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05740-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05740-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:55:12Z","timestamp":1786413312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05740-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":27,"alternative-id":["5740"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05740-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the SFDA ethics committee (ethics approval number: 2025_030) on September 22, 2025. The study does not involve any identifiable data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this paper are those of the authors and do not necessarily reflect those of the SFDA or its stakeholders. Guaranteeing the accuracy and the validity of the data is the sole responsibility of the research team.","order":3,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}